Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The revenue shortfall came alongside an adjusted EPS beat of $0.91 per share. Investors sold on the top-line number. The Company attributed the reduced full-year outlook to a slower-than-expected ramp in its neuroendocrine-tumor business -- a franchise Exelixis had described to investors as a market-leading position for CABOMETYX in the oral second-line plus segment.

Levi & Korsinsky is investigating potential securities law violations at Exelixis, including whether the Company adequately disclosed the condition of its neuroendocrine-tumor commercial ramp before the guidance reduction. On the May 5, 2026 first quarter earnings call, Chief Financial Officer Christopher Senner stated: "Finally, we are reiterating our full year 2026 financial guidance." That guidance was subsequently lowered.

Shareholders who lost money on EXEL are encouraged to contact the firm about their losses. You may also reach Joseph E. Levi, Esq. at [e-mail] or [phone].

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the EXEL Investigation

Q: What is the EXEL investigation about? A: A securities investigation is pending concerning Exelixis (NASDAQ: EXEL) regarding potentially materially false or misleading statements. Shares declined after the Company reported Q2 revenue of approximately $628.7 million, below consensus, and lowered its full-year 2026 revenue guidance citing a slower-than-expected neuroendocrine-tumor ramp.

Q: Who is eligible to participate in the EXEL investigation? A: Investors who purchased EXEL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Exelixis made materially false or misleading statements regarding CABOMETYX commercial performance, the neuroendocrine-tumor business, and the reiteration of full-year 2026 financial guidance.

Q: What do EXEL investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone].

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my EXEL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EXEL and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.

Attorney Advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260812194921/en/

The Exelixis Stock at the time of publication of the news with a fall of -1,16 % to 43,94EUR on Tradegate stock exchange (12. August 2026, 15:45 Uhr).

Schreibe Deinen Kommentar